Corticosteroids in IgA nephropathy: a randomised controlled trial (Q44419929)

2 December 2017

Corticosteroids in IgA nephropathy: a randomised controlled trial (English)

1 reference

randomized controlled trial

2 December 2017

1 reference

1 reference

C Pozzi

1

1 reference

2 December 2017

P G Bolasco

2

1 reference

2 December 2017

G B Fogazzi

3

1 reference

2 December 2017

S Andrulli

4

1 reference

2 December 2017

P Altieri

5

1 reference

2 December 2017

C Ponticelli

6

1 reference

2 December 2017

F Locatelli

7

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

2 December 2017

1 reference

2 December 2017

353

1 reference

2 December 2017

9156

1 reference

2 December 2017

883-887

1 reference

IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States?

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

1 reference

7 January 2021

Therapeutic perspectives in mesangial IgA nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Renal survival rate of IgA nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Prognostic Indicators in Childhood IgA Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Treatment of IgA nephropathy in children: efficacy of alternate-day oral prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Doubling of serum creatinine: is it sensitive and relevant?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2903563-6

7 January 2021

10.1016/S0140-6736(98)03563-6

Identifiers

DOI

1 reference

2 December 2017

1 reference